DIFFUSE LARGE B-CELL LYMPHOMA-RECURRENT
Clinical trials for DIFFUSE LARGE B-CELL LYMPHOMA-RECURRENT explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B-CELL LYMPHOMA-RECURRENT trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B-CELL LYMPHOMA-RECURRENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a drug duo outsmart returning lymphoma?
Disease control Recruiting nowThis phase II trial is testing whether combining two drugs—glofitamab and chidamide—can help people with diffuse large B-cell lymphoma that has come back or not responded to earlier treatment. The study will enroll about 22 adults and measure how many achieve a complete response …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA-RECURRENT
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug cocktail aims to boost CAR T-Cell success in lymphoma
Disease control Recruiting nowThis early-phase trial is testing whether adding two drugs—CC-99282 and rituximab—can help people with non-Hodgkin lymphoma who didn't get a good result from CAR T-cell therapy. The study will enroll 18 adults with relapsed or refractory B-cell lymphoma. Researchers are looking f…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA-RECURRENT
Phase: PHASE1 • Sponsor: Nathan Denlinger • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC